We demonstrate in preclinical cell line and patient-derived xenograft models that ER signaling mediated breast cancer cell growth is maintained in most settings despite de novo or acquired resistance to CDK4/6 inhibitors. This evidence concerns the gene CDK4 and breast cancer.